Silva Judson W, Droppa-Almeida Daniela, Borsuk Sibele, Azevedo Vasco, Portela Ricardo W, Miyoshi Anderson, Rocha Flávia S, Dorella Fernanda A, Vivas Wanessa L, Padilha Francine F, Hernández-Macedo Maria L, Lima-Verde Isabel B
Technology and Research Institute, Tiradentes University, Av. Murilo Dantas, 300, Aracaju, Sergipe, 49032-490, Brazil.
Biotechnology Unit/Center for Technology Development, Federal University of Pelotas, Capão do Leão, Rio Grande do Sul, 96010-900, Brazil.
BMC Vet Res. 2014 Dec 20;10:965. doi: 10.1186/s12917-014-0304-6.
Caseous lymphadenitis (CLA) is an infectious disease that affects small ruminants and is caused by Corynebacterium pseudotuberculosis. This disease is responsible for high economic losses due to condemnation and trim of infected carcasses, decreased leather and wool yield, loss of sales of breeding stock and deaths from internal involvement. Treatment is costly and ineffective; the most cost-effective strategy is timely immunisation. Various vaccine strategies have been tested, and recombinant vaccines are a promising alternative. Thus, in this study, different vaccine formulations using a recombinant protein (rCP40) and the CP09 live recombinant strain were evaluated. Five groups of 10 mice each were immunised with saline (G1), rCP40 (G2), CP09 (G3), a combination of CP09 and rCP40 (G4) and a heterologous prime-boost strategy (G5). Mice received two immunisations within 15 days. On day 30 after primary immunisation, all groups were challenged with a C. pseudotuberculosis virulent strain. Mice were monitored and mortality was recorded for 30 days after challenge.
The G2, G4 and G5 groups showed high levels of IgG1 and IgG2a; G2 presented significant IgG2a production after virulent challenge in the absence of IgG1 and IgG3 induction. Thirty days after challenge, the mice survival rates were 20 (G1), 90 (G2), 50 (G3), 70 (G4) and 60% (G5).
rCP40 is a promising target in the development of vaccines against caseous lymphadenitis.
干酪性淋巴结炎（CLA）是一种影响小型反刍动物的传染病，由伪结核棒状杆菌引起。由于感染胴体的报废和修整、皮革和羊毛产量下降、种畜销售损失以及内部感染导致的死亡，这种疾病造成了巨大的经济损失。治疗成本高昂且效果不佳；最具成本效益的策略是及时免疫。已经测试了各种疫苗策略，重组疫苗是一种有前景的替代方案。因此，在本研究中，评估了使用重组蛋白（rCP40）和CP09活重组菌株的不同疫苗配方。将五组每组10只小鼠分别用生理盐水（G1）、rCP40（G2）、CP09（G3）、CP09和rCP40的组合（G4）以及异源初免-加强策略（G5）进行免疫。小鼠在15天内接受两次免疫。在初次免疫后第30天，所有组均用伪结核棒状杆菌强毒株进行攻毒。对小鼠进行监测，并记录攻毒后30天的死亡率。
G2、G4和G5组显示出高水平的IgG1和IgG2a；G2组在强毒攻毒后产生了显著的IgG2a，而未诱导IgG1和IgG3。攻毒30天后，小鼠存活率分别为20%（G1）、90%（G2）、50%（G3）、70%（G4）和60%（G5）。
rCP40是开发抗干酪性淋巴结炎疫苗的一个有前景的靶点。
